CBIO Q1 2023 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$262,958

Operating Income

-$11M

Net Income

-$10M

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+100.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$870,180

Balance Sheet

Total Assets

$69M

Total Liabilities

$7M

Stockholders' Equity

$62M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$262,958	-$258,122	-1.9%
Operating Income	-$11M	-$15M	+25.4%
Net Income	-$10M	-$15M	+29.3%